Premium
Decreased serum‐soluble TRAIL levels in patients with amyotrophic lateral sclerosis
Author(s) -
Iłżecka J.
Publication year - 2008
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2007.00947.x
Subject(s) - amyotrophic lateral sclerosis , medicine , cytokine , tumor necrosis factor alpha , apoptosis , multiple sclerosis , disease , central nervous system , central nervous system disease , degenerative disease , immunology , endocrinology , gastroenterology , pathology , oncology , biology , biochemistry
Objectives – Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Previously, it was showed that apoptosis may play a role in the pathomechanisms of this disease. Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) is a cytokine with proapoptotic activity in the central nervous system. The aim of the study was to measure serum TRAIL levels in patients with ALS. Materials and methods – The study involved 25 patients with ALS and 20 controls. Serum TRAIL levels were performed by the enzyme‐linked immunosorbent method. Results – Study showed that TRAIL levels were significantly decreased in the serum of patients with ALS compared with controls ( P < 0.05). There was no significant correlation between serum TRAIL levels and clinical parameters of ALS ( P > 0.05). Conclusion – A decrease in serum TRAIL levels in patients with ALS suggests that this cytokine may be implicated in the pathomechanisms of this disease.